Evidence map›Paper›PMID 33486009›Full record

ReviewAdvanced drug delivery reviews2021

Targeting drug delivery with light: A highly focused approach.

Teresa L Rapp, Cole A DeForest

Open access · greenAbstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 156 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Small Fish, Big Answers: Zebrafish and the Molecular Drivers of Metastasis.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Teresa L RappDepartment of Chemical Engineering, University of Washington, Seattle, WA 98105, USA.
Cole A DeForestDepartment of Chemical Engineering, University of Washington, Seattle, WA 98105, USA; Department of Bioengineering, University of Washington, Seattle, WA 98105, USA; Department of Chemistry, University of Washington, Seattle, WA 98105, USA; Institute of Stem Cell & Regenerative Medicine, University of Washington, Seattle, WA 98109, USA; Molecular Engineering & Sciences Institute, University of Washington, Seattle, WA 98105, USA. Electronic address: profcole@uw.edu.
University of Washington · US

Funding

Mimicking, Exploiting, and Understanding Biology's Heterogeneity in 4DR35GM138036 · NIGMS · UNIVERSITY OF WASHINGTON · PI Cole A DeForest · 2020 to 2026
$2.3M
NIGMS NIH HHS R35 GM138036
6 · The paper itself

Abstract

Light is a uniquely powerful tool for controlling molecular events in biology. No other external input (e.g., heat, ultrasound, magnetic field) can be so tightly focused or so highly regulated as a clinical laser. Drug delivery vehicles that can be photonically activated have been developed across many platforms, from the simplest "caging" of therapeutics in a prodrug form, to more complex micelles and circulating liposomes that improve drug uptake and efficacy, to large-scale hydrogel platforms that can be used to protect and deliver macromolecular agents including full-length proteins. In this Review, we discuss recent innovations in photosensitive drug delivery and highlight future opportunities to engineer and exploit such light-responsive technologies in the clinical setting.

Indexed as

Drug Delivery SystemsLightAnimalsBiocompatible MaterialsDelayed-Action PreparationsHumansLiposomesMicellesProdrugsBiocompatible MaterialsDelayed-Action PreparationsLiposomesMicellesProdrugsDual-actionIn vivo drug deliveryLight-mediated deliveryPhotoactivatedPhotochemistryPhotodegradable hydrogelsPhotoresponsive nanoparticlesPhotoswitchesProdrugs

Identifiers

PMID33486009
PMCPMC8127392
OpenAlexW3125500203

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.